1. Akinola S, da Silveira CG, Corbin S, Lavallée M, Thibault M, Midiani Gonella J, Gimenes FRE, Leclerc J. Using data from the canadian post-marketing spontaneous pharmacovigilance system for drug safety research: a feasibility study. Pharmaceut Med. 2020;34(4):263–9.
2. Andreaggi CA, Novak EA, Mirabile ME, Sampathkumar S, Gray MP, He M, Kane-Gill SL. Safety concerns reported by consumers, manufacturers and healthcare professionals: a detailed evaluation of opioid-related adverse drug reactions in the FDA database over 15 years. Pharmacoepidemiol Drug Saf. 2020;29(12):1627–35.
3. Aung AK, Tang MJ, Adler NR, de Menezes SL, Goh MSY, Tee HW, Trubiano JA, Puy R, Zubrinich CM, Graudins LV. Adverse drug reactions reported by healthcare professionals: reaction characteristics and time to reporting. J Clin Pharmacol. 2018;58(10):1332–9.
4. Association des pharmaciens du Canada, Opioïdes (Monographie de l'APhC), in Compendium des produits et
spécialités pharmaceutiques. Ottawa: L'Association des pharmaciens du Canada; 2018.
5. Canadian Cancer Society, Statistic Canada, Public Health Agency of Canada. Canadian cancer statistics. 2019. https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2019-EN.pdf?la=en.